Hostname: page-component-6766d58669-zlvph Total loading time: 0 Render date: 2026-05-14T23:45:00.786Z Has data issue: false hasContentIssue false
  • English
  • Français

Reviewer Comment on Halabi et al. “Safety and Real-World Effectiveness in the Transition from Alteplase to Tenecteplase for Stroke Treatment”

Published online by Cambridge University Press:  21 May 2025

Julián Alejandro Rivillas  and
Alexandre Y. Poppe Open the ORCID record for Alexandre Y. Poppe [Opens in a new window]
Julián Alejandro Rivillas
Affiliation:
Department of Neurosciences, Université de Montréal, Centre Hospitalier de l’Université de Montréal (CHUM), Montreal, QC, Canada Departamento de Salud Pública y Medicina Comunitaria Universidad Icesi, Cali, BC, Canada
Alexandre Y. Poppe*
Affiliation:
Department of Neurosciences, Université de Montréal, Centre Hospitalier de l’Université de Montréal (CHUM), Montreal, QC, Canada
*
Corresponding author: Alexandre Y. Poppe; Email: alexandre.poppe.med@ssss.gouv.qc.ca
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Information

Type
Reviewer Comment
Information
Canadian Journal of Neurological Sciences , First View , pp. 1
Copyright
© The Author(s), 2025. Published by Cambridge University Press on behalf of Canadian Neurological Sciences Federation

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Menon, BK, Buck, BH, Singh, N, et al. Intravenous Tenecteplase compared with Alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial. Lancet. 2022;400:161–169. DOI: 10.1016/S0140-6736(22)00963-3.CrossRefGoogle ScholarPubMed
Wang, L, Hao, M, Wu, N, Wu, S, Fisher, M, Xiong, Y. Comprehensive review of Tenecteplase for thrombolysis in acute ischemic stroke. J Am Heart Assoc. 2024;13;e031692. DOI: 10.1161/JAHA.123.031692.10.1161/JAHA.123.031692CrossRefGoogle ScholarPubMed
Halabi, ML, Stang, J, Menon, B, et al. A study on the transition from alteplase to tenecteplase in acute ischemic stroke care in Alberta: a health system approach. Can J Neurol Sci. 2025.Google Scholar
De Souza, AC, Sebastian, IA, Wan Zaidi, WA, et al. Regional and national differences in stroke thrombolysis use and disparities in pricing, treatment availability, and coverage. Stroke. 2022;53(2):e1–e4. DOI: 10.1161/STROKEAHA.121.0370,Google Scholar